Efficacy of fotemustine in recurrent/progressive gliomas:: A phase II study

被引：0
|
作者：
Laguzzi, E.
Rudà, R.
Trevisan, E.
Guarneri, D.
Mocellini, C.
Soffietti, R.
机构：
[1] Univ Turin, Div Neurooncol, Turin, Italy
[2] Div Neurol, Cuneo, Italy
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：347 / 347
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of fotemustine in recurrent or progressive gliomas
    Trevisan, E.
    Laguzzi, E.
    Ruda, R.
    Guarneri, D.
    Soffietti, R.
    JOURNAL OF NEUROLOGY, 2008, 255 : 19 - 19
  • [2] PHASE-II STUDY OF FOTEMUSTINE IN RECURRENT SUPRATENTORIAL MALIGNANT GLIOMAS
    FRENAY, M
    GIROUX, B
    KHOURY, S
    DERLON, JM
    NAMER, M
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (07) : 852 - 856
  • [3] A PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH FOTEMUSTINE IN RECURRENT ANAPLASTIC GLIOMAS
    Soffietti, Riccardo
    Magistrello, Michela
    Bertero, Luca
    Bosa, Chiara
    Crasto, Stefania Greco
    Garbossa, Diego
    Lolli, Ivan
    Trevisan, Elisa
    Ruda, Roberta
    NEURO-ONCOLOGY, 2012, 14 : 71 - 71
  • [4] BEVACIZUMAB IN COMBINATION WITH FOTEMUSTINE AS SALVAGE THERAPY IN RECURRENT ANAPLASTIC GLIOMAS: A PHASE II TRIAL
    Trevisan, E.
    Magistrello, M.
    Bertero, L.
    Bosa, C.
    Crasto, S. Greco
    Garbossa, D.
    Lolli, I.
    Ruda, R.
    Soffietti, R.
    NEURO-ONCOLOGY, 2012, 14 : 50 - 50
  • [5] A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas
    Raizer, Jeffrey
    Gallot, Lilia
    Levy, Robert
    Getch, Christopher
    Mellot, Ann
    Newman, Steven
    Tellez, Claudia
    Batjer, Hunt
    Marymont, Maryanne
    Chandler, James
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [6] A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas
    Raizer, J. J.
    Gallot, L.
    Cohn, R.
    Chandler, J.
    Levy, R.
    Getch, C.
    Batjer, H.
    Marymont, M.
    Tellez, C.
    Mellot, A.
    Newman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] SALVAGE CHEMOTHERAPY WITH BEVACIZUMAB AND FOTEMUSTINE IN TEMOZOLOMIDE-PRETREATED PATIENTS WITH RECURRENT GRADE III GLIOMAS: A PHASE II STUDY
    Franchino, F.
    Magistrello, M.
    Pellerino, A.
    Nicolotto, E.
    Garbossa, D.
    Bertero, L.
    Trevisan, E.
    Ruda, R.
    Soffietti, R.
    NEURO-ONCOLOGY, 2016, 18 : 56 - 56
  • [8] Fotemustine in recurrent supratentorial malignant gliomas
    Mousseau, M
    Swiercz, P
    Rougny, M
    Boutonnat, J
    Mechin, I
    Chinal, J
    Passagia, JG
    Bolla, M
    Pasquier, B
    Benabid, AL
    Schaerer, R
    DRUGS OF TODAY, 1996, 32 : 43 - 50
  • [9] BEVACIZUMAB AND FOTEMUSTINE FOR RECURRENT HIGH GRADE GLIOMAS
    Sponghini, A. P.
    Platini, F.
    Rondonotti, D.
    Trevisan, E.
    Soffietti, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] Second-line chemotherapy with bevacizumab and fotemustine in temozolomide-pretreated patients with recurrent grade III gliomas: a phase II study
    Franchino, F.
    Magistrello, M.
    Pellerino, A.
    Trevisan, E.
    Ruda, R.
    Soffietti, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 72 - 72
12345